Genomic profiling in clinical practice: where are we going and where are we today? Which are current use and attitudes towards tumor genome sequencing? Which are the benefits for patients of a wider genomic profiling? We interviewed Shridar Ganesan, Chief of Molecular Oncology at the Rutgers Cancer Institute of New Jersey during the Associazione Italiana di Oncologia Medica (AIOM) congress in Rome. Let’s take a look at the future of genome sequencing in clinical practice…
In the future almost every cancer is going to have genomic profile as a part of its classification.
Chief Molecular Oncology Rutgers Cancer Institute of New Jersey
Roma, 29 ottobre 2017 Intervista a cura di David Frati